Remus Pharmaceuticals Ltd

Remus Pharma experienced significant growth from March 2024 to March 2025, with net sales increasing to 620.36 Cr from 212.94 Cr, and profit after tax rising to 38.42 Cr from 24.28 Cr. Key financial metrics, including earnings per share and total assets, also showed substantial improvement.

As of 04-Nov, Remus Pharmaceuticals Ltd is seeing a price increase to 812.50, up 5.51%, with strong short-term performance and increased investor participation. However, it remains down significantly year-to-date and over the past year, contrasting with the broader market's positive trends.

As of November 3, 2025, the technical trend is mildly bearish with weak strength, indicated by bearish weekly MACD and moving averages, despite a bullish monthly RSI, resulting in mixed signals overall.

As of 03-Nov, Remus Pharmaceuticals Ltd's stock price has risen to 770.05, up 6.94% today, but it has underperformed year-to-date with a decline of 38.33%. Despite recent short-term gains, decreasing investor participation and mixed long-term signals suggest potential concerns for future performance.

As of 31-Oct, Remus Pharmaceuticals Ltd is currently priced at 720.05, reflecting a 4.65% increase today and strong investor interest, evidenced by a 105.04% rise in delivery volume. However, the stock has declined 42.34% year-to-date, indicating ongoing long-term challenges despite recent gains.

As of 08-Oct, Remus Pharmaceuticals Ltd's stock price is 667.70, down 4.95% and at a 52-week low. The stock has significantly underperformed its sector and the broader market, despite increased investor participation.

As of 29-Sep, Remus Pharmaceuticals Ltd's stock price is Rs. 734.40, down 3.37%, and has reached a 52-week low of Rs. 725.3. The stock has significantly underperformed its sector and the broader market, with a year-to-date decline of 41.19% and a notable drop in investor participation.

As of 24-Sep, Remus Pharmaceuticals Ltd is priced at 789.45, having increased slightly by 0.45%. However, it has significantly underperformed with a year-to-date decline of 36.78% and is currently trading below all major moving averages, indicating a bearish trend and decreased investor interest.

As of 23-Sep, Remus Pharmaceuticals Ltd's stock price is Rs 785.90, down 1.58%, and has significantly underperformed its sector and the broader market, with a year-to-date decline of 37.07%. Despite increased investor participation, there are no positive catalysts to support a rebound in the stock's price.

As of 22-Sep, Remus Pharmaceuticals Ltd's stock price is Rs 798.50, down 0.34%, and has significantly underperformed with a 1-week decline of 2.62% and a 1-month drop of 15.27%. The stock is trading below its moving averages and is close to its 52-week low, indicating a bearish trend and reduced investor interest.

As of 19-Sep, Remus Pharmaceuticals Ltd is priced at 801.20, up 0.66%, but has declined 2.36% over the past week and significantly underperformed over the past month and year. Despite a recent increase in investor participation, the stock remains below its moving averages and has struggled compared to the benchmark Sensex.

As of 18-Sep, Remus Pharmaceuticals Ltd's stock price is Rs 795.95, down 1.89%, with significant underperformance reflected in a -5.41% return over the past week and -13.13% over the past month. The stock is trading below all key moving averages and is close to its 52-week low, indicating a bearish trend amidst weak investor sentiment.

As of 17-Sep, Remus Pharmaceuticals Ltd is facing a decline in its stock price, currently at 811.25, with significant underperformance reflected in negative returns over the past week and month, and a year-to-date decline of 35.04%. The stock is trading below all moving averages and is close to its 52-week low, indicating weak investor participation compared to the broader market's positive performance.

As of 16-Sep, Remus Pharmaceuticals Ltd is facing a decline in its stock price, currently at 819.35, with a new 52-week low of Rs. 775 and a year-to-date decline of 34.39%. The stock is underperforming its sector and the broader market, indicating a bearish trend and waning investor confidence.

As of 15-Sep, Remus Pharmaceuticals Ltd's stock price is at 820.00, reflecting a decline and a new 52-week low of Rs. 813. The stock has underperformed against the Sensex, with significant losses over various time frames and declining investor interest, indicating continued downward pressure.

As of 12-Sep, Remus Pharmaceuticals Ltd's stock price is 820.55, down 2.49%, and near its 52-week low. The stock has significantly underperformed its sector and the broader market, with a year-to-date decline of 34.29%, indicating a bearish trend and declining investor confidence.

As of 11-Sep, Remus Pharmaceuticals Ltd is facing a significant price decline, currently at Rs 841.50, with a year-to-date drop of -32.61% and trading below all major moving averages. The stock's performance contrasts sharply with the broader market, as it continues to struggle without any positive catalysts for recovery.

As of 10-Sep, Remus Pharmaceuticals Ltd is priced at 843.65, up 1.9% but down 32.44% year-to-date. Despite a recent increase in investor participation, the stock has underperformed compared to the broader market, which has seen gains.

As of 09-Sep, Remus Pharmaceuticals Ltd's stock price is Rs 827.90, down 0.73%, with a year-to-date decline of 33.70%. The stock is underperforming significantly compared to the Sensex, which has increased by 5.18% this year, indicating a bearish trend and decreased investor participation.